These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28860742)

  • 1. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
    Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
    Huang TM; Kuo KC; Wang YH; Wang CY; Lai CC; Wang HC; Chen L; Yu CJ;
    BMC Infect Dis; 2020 Sep; 20(1):706. PubMed ID: 32977747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists.
    Wang CY; Lin YS; Wang YH; Lai CC; Wang HC; Chen L; Yu CJ;
    Aging (Albany NY); 2019 Sep; 11(17):6863-6871. PubMed ID: 31509517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C; Naya I; Ekelund J
    Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety.
    Suissa S; Dell'Aniello S; Ernst P
    Respir Med; 2021; 189():106645. PubMed ID: 34757243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
    Kuna P
    Clin Drug Investig; 2010; 30(9):565-79. PubMed ID: 20593912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations.
    Papi A; Mansur AH; Pertseva T; Kaiser K; McIver T; Grothe B; Dissanayake S
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):346-61. PubMed ID: 27104231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting β
    Chang TY; Chien JY; Wu CH; Dong YH; Lin FJ
    Chest; 2020 May; 157(5):1117-1129. PubMed ID: 31887282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.
    Wang CY; Lai CC; Yang WC; Lin CC; Chen L; Wang HC; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2775-2783. PubMed ID: 27877031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
    Kew KM; Seniukovich A
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010115. PubMed ID: 24615270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
    Solidoro P; Patrucco F; Bagnasco D
    Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
    [No Abstract]   [Full Text] [Related]  

  • 19. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).
    Janson C; Larsson K; Lisspers KH; Ställberg B; Stratelis G; Goike H; Jörgensen L; Johansson G
    BMJ; 2013 May; 346():f3306. PubMed ID: 23719639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
    Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
    Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.